NouBio focuses on developing technologies to unlock cell-based longevity solutions. The company is dedicated to advancing research and applications within the cellular aging field. Their work aims to provide novel pathways for extending healthy lifespan through cellular mechanisms.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell-based biomanufacturing relies heavily on animal serum, particularly fetal bovine serum (FBS), which is expensive, ethically problematic, and faces regulatory hurdles, hindering the scalability and cost-effectiveness of cultivated meat and cell-based therapies. Traditional serum sources also introduce variability and potential contamination risks, impacting the consistency and reliability of cell cultures.
Solution
NouBio provides NouSerum, a synthetic, animal-free serum replacement designed to reduce the costs and risks associated with traditional FBS. NouSerum is a GRAS-certified, scalable, and GMO-free powder containing 300 serum proteins that fully replaces FBS in cell culture applications. By eliminating the need for animal-derived components, NouBio enables more ethical, consistent, and cost-effective cell-based biomanufacturing for cell-based foods, therapies, and industrial synthetic biology. The product enhances cell density and provides antimicrobial properties, improving overall cell culture performance.
Target Audience
The primary target audience includes companies in the cell-based food, cell-based therapies (vaccines, cell therapy, biosimilars, human tissue, & regenerative medicine), and industrial cell-based synthetic biology industries.
Features
- Complete FBS replacement with a synthetic serum powder containing 300 serum proteins
- GRAS-certified and free from GMOs, ensuring regulatory compliance and consumer acceptance
- Scalable production to meet the growing demands of the cell-based biomanufacturing industry
- Enhanced cell density and antimicrobial properties for improved cell culture performance
- Reduces cell-based biomanufacturing costs by 50-95% compared to traditional FBS